TABLE 1.
Rifampin, rifapentine, and rifabutin drug exposure achieved in the HFS-MAC.
| Regimen | Drug | fCmax (mg/L) | fAUC0-24 (mg*hr/L) | fCmax/MIC | fAUC0-24/MIC |
|---|---|---|---|---|---|
| RIF-1 | Rifampin | 0.76 | 5.79 | 26.54 | 192.97 |
| RIF-2 | Rifampin | 2.03 | 19 | 67.63 | 633.33 |
| RIF-3 | Rifampin | 4.12 | 39.84 | 137.2 | 1328 |
| RFP-1 | Rifapentine | 0.15 | 1.38 | 5.1 | 46.1 |
| RFP-2 | Rifapentine | 0.17 | 2.22 | 5.62 | 73.87 |
| RFP-3 | Rifapentine | 1.02 | 13.05 | 33.93 | 435 |
| RFB-1 | Rifabutin | 1.05 | 12.52 | 35 | 417.33 |
| RFB-2 | Rifabutin | 1.98 | 26.91 | 66.07 | 897 |
| RFB-3 | Rifabutin | 3.48 | 48.19 | 115.87 | 1606.33 |
| CTL-1 | Non-treated | – | – | – | – |
| CTL-2 | Non-treated | – | – | – | – |
| CTL-3 | Non-treated | – | – | – | – |